122 Stock Chart & Stats
€4.66
€0.00(0.00%)
At close: 4:00 PM EDT
€4.66
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€4.28 - €4.66
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€12.37M
Enterprise Value€25.56M
Total Cash (Recent Filing)€12.62M
Total Debt (Recent Filing)€6.76M
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 05, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding19,669,083
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)75.90
Price to Sales (P/S)209.43
P/FCF Ratio-21.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.91Price Target Upside91.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.84
Revenue Forecast (FY)€1.87M
Bulls Say, Bears Say
Bulls Say
Commercialization ProgressLaunching a first directly commercialized product advances Daré beyond development-stage activity and creates an initial platform for recurring revenue. It also gives the company practical experience in consumer reach, fulfillment, and market adoption that can support future women’s health products.
Clinical Pipeline ProgressPositive interim Phase III data and an unchanged DSMB recommendation support the program’s clinical trajectory and preserve a path toward future regulatory engagement. If later results remain supportive, Ovaprene could materially broaden Daré’s contraception portfolio and commercial opportunity.
Non-Dilutive Program FundingNon-dilutive funding helps Daré advance clinical programs while reducing the immediate need to finance all research spending through equity issuance. This support can extend development capacity, validate external interest, and preserve resources for multiple women’s health candidates.
Bears Say
Persistent Operating LossesRevenue remains too small to cover the company’s operating base, and negative gross profit combined with a substantial EBIT loss shows that commercial scale has not yet translated into economic sustainability. Continued losses may restrict investment flexibility and require further financing.
Cash Burn And Balance-Sheet StrainOngoing negative operating and free cash flow indicate that Daré is consuming capital to fund operations rather than generating internal cash. Combined with negative equity, this reduces financial flexibility and increases dependence on external funding to sustain development and commercialization.
Nasdaq Listing Compliance RiskThe minimum-bid deficiency creates a continuing corporate and financing risk because failure to restore compliance could ultimately lead to delisting. A listing disruption could complicate access to capital markets, reduce institutional participation, and constrain strategic flexibility during commercialization.
Daré Bioscience News
122 FAQ
What was Daré Bioscience Inc’s price range in the past 12 months?
Daré Bioscience Inc lowest stock price was €4.28 and its highest was €4.66 in the past 12 months.
What is Daré Bioscience Inc’s market cap?
Daré Bioscience Inc’s market cap is €12.37M.
When is Daré Bioscience Inc’s upcoming earnings report date?
Daré Bioscience Inc’s upcoming earnings report date is Nov 05, 2026 which is in 14 days.
How were Daré Bioscience Inc’s earnings last quarter?
Daré Bioscience Inc released its earnings results on Aug 13, 2026. The company reported -€0.178 earnings per share for the quarter, beating the consensus estimate of -€0.264 by €0.086.
Is Daré Bioscience Inc overvalued?
According to Wall Street analysts Daré Bioscience Inc’s price is currently Undervalued.
Does Daré Bioscience Inc pay dividends?
Daré Bioscience Inc does not currently pay dividends.
What is Daré Bioscience Inc’s EPS estimate?
Daré Bioscience Inc’s EPS estimate is -0.12.
How many shares outstanding does Daré Bioscience Inc have?
Daré Bioscience Inc has 19,669,083 shares outstanding.
What happened to Daré Bioscience Inc’s price movement after its last earnings report?
Daré Bioscience Inc reported an EPS of -€0.178 in its last earnings report, beating expectations of -€0.264. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Daré Bioscience Inc?
Currently, no hedge funds are holding shares in DE:122
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Daré Bioscience Inc
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
122 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call described meaningful operational and clinical progress — a first product launch, an approaching prescription product with early prescription activity, positive Phase III interim data for Ovaprene, and non-dilutive funding supporting R&D. However, these positives are balanced by constrained near-term financials: modest Q2 revenue ($200k), limited cash ($12.6M) with a slight working capital deficit, a sizable deferred grant liability (~$15M), and ongoing net losses. Regulatory nuance around Ovaprene completers and the fact that DARE-VVA1 is not yet dispensing also add execution and timing risk. Overall, the update reflects promising commercial and clinical momentum but with material near-term financial and execution challenges.View all DE:122 earnings summaries122 Stock 12 Month Forecast
Average Price Target
€8.91
▲(91.29% Upside)
Technical Analysis
Vyome Holdings
―
Lunai Bioworks
―
Passage Bio
―
Neurosense Therapeutics Ltd.
―
Boundless Bio Inc.
―